ENDRA Life Sciences Inc.

The information set forth below is included herein for the purpose of providing the disclosure required under “Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.” of Form 8-K.

On August 14, 2025, the Company filed a Certificate of Correction (the “Certificate of Correction”) to its Certificate of Amendment of Certificate of Incorporation (the "Certificate of Amendment") filed with the Secretary of State of the State of Delaware on November 4, 2024.

The Certificate of Amendment inadvertently stated in the opening sentence of Article FIRST thereof that the text of both the first and second paragraphs of Article FOURTH of the Certificate of Incorporation of the Company were to be deleted in their entirety when it was intended that solely the text of the second paragraph of Article FOURTH of the Certificate of Incorporation of the Company was to be deleted in its entirety.

The Fourth Amended and Restated Certificate of Incorporation of the Company, as filed as Exhibit 3.1 hereto, reflects the above-described Certificate of Correction, and the foregoing description of the Certificate of Correction is qualified in its entirety by reference to the text of Exhibit 3.1 hereto and the Certificate of Amendment, filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 5, 2024.

Rule 10b5-1 Trading Plans

None of the Company’s directors or officers adopted, modified, orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended June 30, 2025.